TY - JOUR
T1 - Anticancer properties of zoledronic acid
AU - Green, Jonathan
AU - Lipton, Allan
N1 - Funding Information:
Declaration of interest: Dr. Green consults for, owns stock in, and has provided expert testimony for Novartis Pharmaceuticals Corporation; he was previously employed with No-vartis Pharmaceuticals Corporation. Dr. Lipton consults for Amgen, Inc. and Novartis Pharmaceuticals Corporation; he has received honoraria from Amgen, Inc., Genentech, Inc., and No-vartis Pharmaceuticals Corporation; has received research funding from Novartis Pharmaceuticals Corporation and Monogram Biosciences; and has provided expert testimony for Novartis Pharmaceuticals Corporation. However, the authors are fully responsible for all the content and editorial decisions in respect of this manuscript.
Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2010/10
Y1 - 2010/10
N2 - Zoledronic acid effectively reduces/delays skeletal-related events in patients with metastatic disease or skeletal-related cancers. Emerging data suggest that zoledronic acid may also exhibit anticancer properties. Zoledronic acid ± anticancer therapies in animal models inhibits soft-tissue tumor growth, decreases tumor cell proliferation, increases apoptosis, inhibits angiogenesis, alters tumor-associated macrophage function, and enhances immune surveillance. Data from in vitro and pilot studies suggest that zoledronic acid inhibits tumor cell dissemination in bone marrow, and early clinical data show that it may improve disease-related outcomes. Ongoing studies will further elucidate the role of zoledronic acid in cancer patients.
AB - Zoledronic acid effectively reduces/delays skeletal-related events in patients with metastatic disease or skeletal-related cancers. Emerging data suggest that zoledronic acid may also exhibit anticancer properties. Zoledronic acid ± anticancer therapies in animal models inhibits soft-tissue tumor growth, decreases tumor cell proliferation, increases apoptosis, inhibits angiogenesis, alters tumor-associated macrophage function, and enhances immune surveillance. Data from in vitro and pilot studies suggest that zoledronic acid inhibits tumor cell dissemination in bone marrow, and early clinical data show that it may improve disease-related outcomes. Ongoing studies will further elucidate the role of zoledronic acid in cancer patients.
UR - https://www.scopus.com/pages/publications/77957977187
UR - https://www.scopus.com/pages/publications/77957977187#tab=citedBy
U2 - 10.3109/07357907.2010.512598
DO - 10.3109/07357907.2010.512598
M3 - Review article
C2 - 20879838
AN - SCOPUS:77957977187
SN - 0735-7907
VL - 28
SP - 944
EP - 957
JO - Cancer Investigation
JF - Cancer Investigation
IS - 9
ER -
